Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Amgen

Bristol-Myers

Currently, there are many indicators showing that the U.S. stock market is overvalued.

3 Big Pharma Stocks Trading Near 52-Week Lows

KDDI Corp

Lockheed Martin

Altria

Unilever

High inflation, low-interest rates, and a 30% overvalued S&P create a perfect storm for retirees worried about making ends meet. Fortunately, the world's best high-yield Ultra SWANs can still help you beat inflation, retire rich, stay rich in retirement, and likely let your children and grandchildren retire even richer.

The 5 Safest High-Yield Blue-Chips Retirees Can Buy Today

Johnson & Johnson

Pfizer

S&P 500 investors can expect an average annual return of 7%, with upside potential based on the speed of technological innovation, according to DataTek Research.

Pfizer, J&J and Novartis Capture Top 3 Spots in Innovation Index

Applied Materials

Coinbase

Intel

StoneCo

Patient investors who overcome short-term distractions will get a windfall with these stocks to buy, as they're set to grow at a faster pace. The post 7 Stocks to Buy That Will Make You Rich by 2030 appeared first on InvestorPlace.

7 Stocks to Buy That Will Make You Rich by 2030

Alcon Inc. - Registered Shares

Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.

Alcon Big Winner in 2019 Divorce From Novartis

Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia.  The move will take effect next February, Xencor Inc (NASDAQ: XNCR) said.

Novartis Dumps Another Bispecific Candidate From Xencor Deal

Atmos Energy

Colgate-Palmolive

Con Ed

Hormel Foods

Kimberly-Clark

Northwest Natural Gas

The market is up 8% in a few weeks, and the 28% overvalued S&P 500 offers near-zero inflation and risk-adjusted expected returns over the next five years. Fortunately, there are always wonderful blue-chips available at reasonable to attractive prices, even high-yield, low-volatility dividend aristocrats.

The 10 Safest High-Yield Dividend Aristocrats To Buy With The Market At Record Highs

Roche Holding AG

Roche's $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an interview published on Saturday.

Roche chairman sees greater flexibility after Novartis deal - paper

Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active alternative complement pathway causes deposits of C3 protein to build up in blood vessels that filter waste and remove extra fluids from the blood.

Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial

Basel, November 4, 2021 — Novartis will highlight new data on Scemblix® (asciminib), recently approved by the US Food and Drug Administration, as well as its next-generation CAR-T platform and the latest research results for an array of hematology medicines at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (December 11-14; Atlanta and virtually). More than 100 abstracts, including 24 oral presentations, will be shared at the meeting.

New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting stake in Roche for $20.7 billion. The deal means that Novartis will give up its influence over strategic decisions taken by Roche.

Novartis To Offload Its Stake Back To Roche For $20.7B

A Roche shareholder since 2001, Novartis expects to report a gain of $14 billion from the stake sale, which disentangles two pharma rivals.

Novartis Will Sell Back Its Roche Stake for $21 Billion. Both Stocks Are Rising.

Novartis AG and Roche Holding AG said Thursday that the Swiss pharmaceutical companies have agreed for Novartis to sell its holding of Roche bearer shares to Roche for a total consideration of $20.7 billion.

Roche climbs on deal to buy back $21 billion stake held by Novartis

Novartis AG, a shareholder in Roche for more than 20 years, said on Thursday the two Swiss drugmakers had agreed that Roche would buy Novartis's nearly one-third voting stake in its cross-town rival for $20.7 billion.

Novartis sells its Roche stake to Roche for $20.7 billion

The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally bioavailable covalent and protein degrading small molecule drugs. Under the new deal, Dunad is tasked with deploying its platform to generate new candidates against up to four targets and steer those programs up to lead optimization.

Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad

The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications.  The FDA granted Scemblix accelerated approval for adult patients with Philadelphia chromosome-positive CML in chronic phase previously treated with two or more tyrosine kinase inhibitors (TKIs).

FDA Approves Novartis' Scemblix In Two Chronic Myeloid Leukemia Settings

Verizon

After 33 weeks and $3,400, the Dividend Harvesting Portfolio is generating $229.63 in estimated annual income and $19.14 in monthly estimated income. In week 34, I added Bristol-Myers Squibb to the portfolio and increased my position in Verizon.

Dividend Harvesting: Week 34 Update, $3,400 Allocated, $229.63 In Annual Dividends Yielding 6.7% With 50 Positions

Following three years of speculation, Novartis AG ( NVS , Financial) may be ready to split off its Sandoz unit. The latter, which has operated with minimal input from its parent since 2018, may gain full independence, according to Fierce Pharma.

Novartis Ponders Fate of Its Sandoz Generics Unit

Shares of Novartis have been overlooked by Mr. Market as they have increased their revenue, net income, and free cash flow, while repurchasing 5.79% of shares outstanding. Novartis has paid 24 years of consecutive dividends and currently pays an annual dividend of $3.20 which is a forward yield of 3.77%.

Novartis: Loving The 3.77% Yield, Growing Financial Strength, And Beautiful Fundamentals

Eli Lilly

On Monday, Eli Lilly And Co (NYSE:LLY) and Novartis AG (OTCMKTS:NVSEF) shares edged higher after announcing their most recent quarterly results. Eli Lilly's revenue and earnings missed expectations while Novartis beat on earnings and matched top-line estimates.

Is Eli Lilly or Novartis the better buy after Q3 results?

Novartis AG (NVS) CEO Vas Narasimhan on Q3 2021 Results - Earnings Call Transcript

Novartis (NVS) reports mixed results in the third quarter, as key brands maintain momentum but generics business remains weak.

Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review

Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 26, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Novartis: Q3 Earnings Insights

Novartis reports rise in sales and earnings, backs guidance

Novartis's third-quarter adjusted operating profit rose 10% as the Swiss drugmaker lifted its peak sales estimate for its two most important pharmaceuticals.

Novartis more bullish on Cosentyx, Entresto sales as Q3 profit rises

News for Novartis Stock (NVS)